The pharmaceutical company Sanofi has reduced its supply of flu vaccines to Ukraine during the current epidemic season, delivering 100,000 doses with no additional deliveries planned.
According to information provided to Interfax-Ukraine by the pharmaceutical company, it supplied 250,000 doses to Ukraine during the previous epidemic season.
“The reduction in deliveries of Sanofi influenza vaccines this season is due to temporary difficulties in production processes, including the company’s global transition to the production of trivalent vaccines in accordance with updated WHO recommendations. The adaptation of technological and logistical processes is currently underway, which has temporarily affected the volume of vaccine supplies to countries in the northern hemisphere, including Ukraine. No additional vaccine supplies are expected this year,” the company said.
In addition, the company reported that Sanofi’s quadrivalent influenza vaccine, which was imported in the amount of 100,000 doses, remains the only vaccine registered by the Ministry of Health in Ukraine for the 2025/2026 epidemic season.
Currently, the media and social networks are reporting a significant shortage of flu vaccines during the current epidemic season. Private clinics are reporting that it is impossible to purchase the vaccine.
The Interfax-Ukraine agency is awaiting comments on the vaccine situation during the current epidemic season from the Ministry of Health, the State Emergency Service, and the State Service of Ukraine on Medicines and Drugs Control.
As reported, as of the end of September 2025, the State Medical Service announced that the first 76,000 doses of the Korean vaccine GC FLU, manufactured by GC BioPharma Corp. and imported by Biolabs LLC, had passed quality control. The quality control procedure was also passed by 100,000 doses of the French vaccine VAXIGRIP TETRA, manufactured by Sanofi Pasteur and imported by Sanofi-Aventis Ukraine LLC. In early October, Biolabs LLC planned to import another 54,000 doses of the GC Flu vaccine manufactured by GC Biopharma Corp.
Since the beginning of the epidemiological season, which started on October 4, 2021, until December 19, 2021, about 7% of Ukrainians have had flu and acute respiratory viral infections (ARVI), including COVID-19, the Public Health Center (PHC) at Ukraine’s Ministry of Health reported on Wednesday.
“In general, since the beginning of the epidemic season, from October 4 to December 19, 2021, some 7.0% of the country’s population has been ill [influenza and ARVI],” the message says.
The Public Health Center reported that during the specified period 3,220 Ukrainians fell ill with influenza-like diseases, 5,344 – with severe acute respiratory infection. At the same time, no deaths due to influenza have been registered.
In general, throughout Ukraine, the circulation of influenza viruses has not been recorded.
“From December 13 to 19, 2021, in Ukraine, a total of 187,510 people fell ill with ARVI, including coronavirus infection, of which 50.6% are children under 17 years. Circulation of influenza viruses is not registered. Incidence rate is 496.0 per 100,000 of population, which corresponds to a low level of the epidemic process intensity. However, this is 3.6% higher than the indicator for the same period of the last season,” the PHC said.
The center said that a low level of influenza and ARVI activity during the last week was observed in 15 regions of Ukraine and Kyiv. In other regions of Ukraine, epidemic activity of varying intensity was recorded.
Domestic pharmaceutical manufacturers are negotiating to localize the production of influenza vaccines in Ukraine, the vaccine will be presented on the market in the first quarter of 2022, Deputy Minister of Health, Chief State Sanitary Doctor Ihor Kuzin said in an online interview with medical expert of the United Nations Children’s Fund (UNICEF) in Ukraine Kateryna Bulavinova.
“Ukrainian pharmaceutical manufacturers are negotiating to localize the production of influenza vaccines in Ukraine. It will be a tri- or quadrivalent vaccine in monodose syringes. We hope that such a vaccine will be available on the market during the first quarter of 2022,” he said.
Kuzin noted that it is also planned to purchase about 1 million doses of the vaccine.
“According to forecasts, we will have the same influenza epidemic season as last year. Since June we have been working with vaccine manufacturers and the pharmaceutical sector. Negotiations are underway to transfer a free vaccine to vaccinate health workers within the humanitarian aid framework. The amount of vaccine that will be supplied to the country for the pharmacy network will be slightly more than last year – about 1 million doses,” the deputy minister said.
INFLUENZA, PHARMACEUTICAL MANUFACTURERS, PRODUCTION, VACCINES
The first batch of influenza vaccines produced by Sanofi Pasteur (France) and Green Cross Corporation (Korea) in the amount of 103,55 dosages were delivered to Ukraine, the press service of the Public Health Center of Ukraine reported on Facebook.
According to the report, vaccines are currently at the stage of quality and safety control.
The approximate deadline for state quality control is October 1, 2019, after which the vaccines will be sold.
In general, Ukraine is to accept 500,000 of dosages of vaccines for influenza immunoprophylaxis.
GREEN CROSS CORPORATION, INFLUENZA, SANOFI PASTEUR, VACCINES
